Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay
Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2
If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer -- Barrons.com
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)
Because Mena announced the expansion of the TruSight Oncology product line.
The latest solutions will be showcased at the annual meeting of the Molecular Pathology Association for comprehensive variant analysis of tumors. Research and share led by customers of Illumina will provide the latest tumor analysis evidence and related content. San Diego, California, USA, November 20, 2024 /PR Newswire/ -- Illumina, a global leader in DNA sequencing and array technologies (nasdaq: ILMN), today announced the launch of the new version of its flagship cancer research testing product, TruSight Oncology 500 v2 (TSO 500 v2), for practical applications.
Express News | Illumina Inc: Trusight Oncology 500 V2 Assay Is Currently Under Development, Global Release Planned for Mid-2025
Express News | Illumina Announces Expansion of Trusight Oncology Portfolio
Illumina Announces Expansion of TruSight Oncology Portfolio
Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now?
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Citi Maintains Illumina(ILMN.US) With Buy Rating, Maintains Target Price $190
Illumina Coverage Resumed at Equal Weight by Morgan Stanley
ARKK's Holdings Ranked by SA Quant Grades
Stephens Maintains Illumina(ILMN.US) With Buy Rating, Raises Target Price to $184
Illumina Price Target Raised to $184 From $170 at Stephens
Morgan Stanley Maintains Illumina(ILMN.US) With Hold Rating, Cuts Target Price to $156
Illumina, Inc. (ILMN): Unlocking Growth Potential in Genetic Testing and Robotics
Illumina Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Illumina(ILMN.US) With Buy Rating, Cuts Target Price to $185
Express News | Illumina Inc : Piper Sandler Cuts Target Price to $185 From $195